News
Risk Reduction in the News – Response from the NLN Medical Advisory Committee
2012 Conference featured in Oncology Times
Clinical Trials - Patient Participation
NLN Position Papers: Risk Reduction, Risk Reduction Summary, Diagnosis and Treatment, Exercise, Training, Breast Cancer-Related Lymphedema, Supplement BC-Related LE
By: Robert Weiss, M.S., Chair NLN Legislative Committee
After ten years of hard work by scores of volunteers, we are taking the next step towards advancing the rights of lymphedema patients for access and coverage of treatment. In the year following Representative Larry Kissell's introduction of his H.R. 4662 "Lymphedema Diagnosis and Treatment Cost Saving Act of 2010" in the House of Representatives, the bill garnered 58 Cosponsors from both sides of the aisle and from across the political spectrum. This first comprehensive lymphedema bill to be introduced in Congress has been rewritten to reflect the suggestions of scores of lymphedema patients, therapists, suppliers, manufacturers and organizations into a new bill introduced by Representative Kissell in the 112th Congress.
Representative Kissell's H.R. 2499 IH Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011 amends title XVIII (Medicare) of the Social Security Act to improve the diagnosis and treatment of lymphedema under the Medicare program, and to reduce costs under such program related to the treatment of lymphedema-related infection, disability and other complications. Specific provisions of the bill are as follows:
For the exact wording of H.R. 2499 and for the latest on its cosponsors, progress through Congress and related bills go to the THOMAS Library of Congress website http://thomas.loc.gov/home/thomas.php and enter the word "lymphedema" or the bill number "HR2499" into the search box.
Congressman Kissell's Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011 H.R. 2499 IH should be supported vigorously. The bill promises to fill most of the gaps in Medicare coverage of lymphedema that have long been identified and are the sources of pain, expense, disability and patient non-adherence. It is estimated that enactment of this bill has the potential of saving Medicare hundreds of millions of dollars through prevention of lymphedema-related cellulitis [Weiss 2005].
Consideration should be given to restoring some of the patient protection provisions that were deleted from earlier versions, predominantly: the training and proficiency requirements for lymphedema therapists; inclusion of lymphedema-trained nurses, physicians and NPPs as providers of lymphedema services; requirement of lymphedema awareness for prescribing and referring physicians; manufacturer certification of garment fitters; and prohibition of denials by non-lymphedema-aware personnel. If you as a patient, or a therapist, feel that your patient protection concerns are not being met by this latest version of the bill, you may write to Congressman Kissell and express your opinions with a request that his bill be amended.
For the latest information on the bill, and live connections to your Congressional Representatives, go to the bill website http://www.lymphedematreatmentact.org.
Author's note:
Whatever the outcome of this bill, I strongly recommend that activities commence with the goal of changing C.F.R. 42 §484.4 Personnel Qualifications to define a new Medicare-qualified provider, i.e. "lymphedema therapist", with associated lymphedema training and certification accreditation requirements. The definition would define which licensed providers (e.g. PTs, OTs, S-LPs, physicians, NPPs and nurses), who, when adequately trained and certified as "proficient" by appropriate accrediting entities approved by the Secretary of DHHS, would be qualified to be reimbursed for providing lymphedema therapy to Medicare beneficiaries within the scope of their basic licensure.